PRIMARY STUDY
Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice
Key Findings: Results suggest intraperitoneal application and intrarectal delivery of cannabinoids may represent a useful therapeutic administration route for the treatment of colonic inflammation.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Austria
Year of Pub: 2012
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Dosage: CBD intraperitoneally (10 mg/kg), orally (20 mg/kg) or intrarectally (20 mg/kg).
Route of Administration: Injection, Oral (Ingestion), Rectal
Link to study
